High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome.
about
Skp2: a novel potential therapeutic target for prostate cancerDysregulation of ubiquitin ligases in cancerCurcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survivalMitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2.Skp2 is a promising therapeutic target in breast cancer.The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesisMolecular prognostic factors in patients with pancreatic cancer.Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cellsRottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells.Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells.Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
P2860
Q24625558-FD885186-0737-418C-A3E6-6C0310242346Q28086796-63786FA2-8E36-4AA2-A48B-12366B59AEA3Q33650304-A7BDC4CE-4B4D-4606-9202-8791B01D21C1Q33840856-5437C877-985A-42CF-8A58-D44C03323864Q34866982-BBB3CFCE-48E1-46B4-BC12-78837D55C2FEQ35687208-B8342FB0-8871-40AF-868E-1D80EA4156E3Q36305395-45060EA6-0F2E-47DF-AD99-08ABCC7185FDQ37004734-BC39BBC9-2646-4D4E-A901-B63FB137977DQ37298290-4D3A07C6-BB85-4DEC-80A1-56C2B6124F9BQ37382511-03BDBC86-EE96-44CF-B096-CA01915E0F15Q37711659-5FEC4A55-25E2-4EC8-8501-6E35B8D8FBDFQ37716398-E09117C2-0D1E-4082-91C8-D9FB4F7832EEQ37832684-8DC5DBF7-002E-414E-A570-23EA0D7AB830Q37971404-EFDC1DBF-FD10-40B7-8BC0-DD4FEB1AEB63Q38293424-230C0DDC-1B89-4FAE-B9F7-C1B2EC4FBFCB
P2860
High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
High-level Skp2 expression in ...... e, and poorer patient outcome.
@en
High-level Skp2 expression in ...... e, and poorer patient outcome.
@nl
type
label
High-level Skp2 expression in ...... e, and poorer patient outcome.
@en
High-level Skp2 expression in ...... e, and poorer patient outcome.
@nl
prefLabel
High-level Skp2 expression in ...... e, and poorer patient outcome.
@en
High-level Skp2 expression in ...... e, and poorer patient outcome.
@nl
P2093
P1433
P1476
High-level Skp2 expression in ...... e, and poorer patient outcome.
@en
P2093
Daisaku Morita
Hitoshi Tsuda
Kazuhiko Fukatsu
Kazuo Hatsuse
Nobuaki Kawarabayashi
Osamu Matsubara
Shigeto Ueda
Takahiro Einama
Toshimichi Takigawa
P304
P356
10.1097/01.MPA.0000220862.78248.C4
P577
2006-05-01T00:00:00Z